Reduce your company's energy expenses through the BIO Business Solutions program's newest initiative. BIO has aligned with APPI Energy, an energy consulting firm, to assist its member companies save on electrical and natural gas costs.
Monsanto said it would give Brazilian farmers who drop their claims that the patent has expired on the company's older Roundup Ready soybean seeds a 16% discount on its Intacta biotech soybean, which is being launched on the Brazilian market.
Servier paid Galapagos about $4 million in milestone fees for identifying new small molecules against a novel target for osteoarthritis. "Today's achievement is consistent with our strategy to move multiple, novel mechanism-of-action programs toward the clinic, thereby increasing the chances of success in disease areas with high unmet medical needs," said Onno van de Stolpe, Galapagos' CEO.
The FDA has accepted Merck & Co.'s application to market its blood clot drug vorapaxar. The anticoagulant is being developed to prevent heart attacks and strokes in patients with a history of heart attack but not stroke.
Roche Holding's investigational drug obinutuzumab, in combination with chemotherapy, slowed the progression of chronic lymphocytic leukemia better than rituximab in a late-stage trial. Obinutuzumab is a monoclonal antibody that stimulates a patient's immune system to fight cancer cells.
CV Therapeutics announced it plans to cut about 110 sales representative jobs as it reduces its sales territories from 250 to 140 as part of a cost-saving move. The firm also plans to seek partnerships with other firms for its products, particularly its Ranexa for treating chronic chest pain.